News

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.
CSPC Pharmaceutical Group Ltd. announced June 13 that it struck a potential $5.33 billion deal with Astrazeneca plc to ...
Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. UBS upgraded ...
For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.
In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.
If finalized, the deal, which was also signed on to by the District of Columbia and U.S. territories, would pay out over the next 15 years. Also: Eli Lilly's experimental weight loss drug, a new Lupus ...
U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 300 points during the session after Iran ...
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...
U.S. stocks closed higher on Monday, as oil prices retreated after the Israel-Iran attacks left crude production and exports ...
US stocks closed higher as Iran aims to deescalate the clash with Israel. Oil prices eased. Fed meets on rates this week. No one expects a rate cut.
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...